Glucagon‐like pepetide‐1 receptor agonist suggests novel therapeutic options for hypothalamic obesity

Glucagon‐like pepetide‐1 receptor agonist suggests novel therapeutic options for hypothalamic obesity

Saved in:

Bibliographic Details
Main Authors:	Wanlu Ma, Bo Zhang, Xiaoping Chen
Format:	Article
Language:	English
Published:	Wiley 2025-03-01
Series:	Journal of Diabetes Investigation
Online Access:	https://doi.org/10.1111/jdi.14372
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-like peptide-1 receptor agonists as a Therapeutic Option for Antipsychotic-Induced Obesity: A Review of Current Evidence
by: Natalia Gniaź, et al.
Published: (2024-12-01)

Mechanism of glucagon-like peptide-1 receptor agonist in the treatment of obesity and food addiction
by: LIU Luyao, LI Linwei, WANG Chen, DI Jianzhong
Published: (2025-06-01)

Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety
by: Michał Stasiak, et al.
Published: (2025-06-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders
by: Junchen Si, et al.
Published: (2025-04-01)

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
by: R. R. C. New, et al.
Published: (2024-11-01)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes
by: Richard J. MacIsaac, et al.
Published: (2024-10-01)

Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
by: Sarah L Anderson
Published: (2025-07-01)

Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology
by: Е. L. Nasonov, et al.
Published: (2024-04-01)

A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity
by: Ibrahim Abdullah bin Ahmed
Published: (2024-01-01)

Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity
by: Alina Yu. Babenko, et al.
Published: (2019-01-01)

Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
by: N.M. Bobok
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
by: Zhi Dong Zhou, et al.
Published: (2025-06-01)

Multiomics insight into the role of glucagon‐like peptide‐1 receptor agonists in heart failure
by: Yuhang Tao, et al.
Published: (2025-08-01)

The Effect of Glucagon-Like Peptide-2 Receptor Agonists on Colonic Anastomotic Wound Healing
by: Heather A. Redstone, et al.
Published: (2010-01-01)

Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
by: Rui Song, et al.
Published: (2022-01-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

The current and changing role of glucagon-like peptide-1 receptor agonists in knee osteoarthritis
by: Anne D. Holleman, et al.
Published: (2025-09-01)

Research progress on mechanisms of glucagon-like peptide-1 receptor agonists in diabetic retinopathy
by: HE Cuihuan, SHI Derong, SUN Dandan, LI Yurui, XIA Guanghao
Published: (2025-02-01)

Glucagon‐Like Peptide‐1 Receptor Agonists and Anesthesia—Are We Clearer on the Correct Approach?
by: Zachary Bloomgarden
Published: (2024-12-01)

Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients
by: Luis Alberto Vigara, et al.
Published: (2024-11-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

Glucagon-like peptide-1 receptor agonists inhibit the progression of malignant pleural effusion in obese mice by regulating the metabolism of pleural effusion
by: Ming-Ming Shao, et al.
Published: (2025-08-01)

Health Disparity Clusters of Off Label Prescriptions for Glucagon-Like Peptide 1 Receptor Agonists
by: Kateri J. Spinelli, et al.
Published: (2025-06-01)

Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective
by: Yosra Turkistani
Published: (2025-04-01)

Meta-analysis of the efficacy of glucagon-like peptide-1 receptor agonists in the treatment of diabetic nephropathy
by: Ze-jin Liao, et al.
Published: (2024-12-01)

Efficacy of Dual Glucagon and Glucagon-like Peptide-1 Receptor Agonists Across the Cardiometabolic Continuum: A Review of Current Clinical Evidence
by: Panagiotis Stachteas, et al.
Published: (2025-07-01)

Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis
by: Deep Dutta, et al.
Published: (2025-05-01)

Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review
by: Ammar Ahmed, et al.
Published: (2024-12-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Glucagon-Like Peptide-1 Receptor agonists: A magic bullet or a double-edged sword?
by: Rachel S. Mandelbaum, M.D.
Published: (2025-03-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.
by: Aiysha Thompson, et al.
Published: (2016-01-01)

Antihypertensive Effect of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists
by: Marijana Tadic, et al.
Published: (2024-03-01)

Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
by: Tyler S. Oesterle, et al.
Published: (2025-06-01)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
by: Dan Xu, et al.
Published: (2022-01-01)

Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
by: Yu-Xuan Yao, et al.
Published: (2025-12-01)

Euglycemic Ketoacidosis After the Addition of Glucagon-Like Peptide-1 Receptor Agonist: A Case Report
by: Ernest Oji Kanu, et al.
Published: (2024-06-01)

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01)